Salvage Systemic Therapy for Advanced Urothelial Carcinoma: On the Cusp of a Sea Change?-Reference-Cited by-同舟云学术

Salvage Systemic Therapy for Advanced Urothelial Carcinoma: On the Cusp of a Sea Change?

Published:2015-04-06 Issue:5 Volume:20 Page:461-463
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Sonpavde Guru¹,Bellmunt Joaquim²

Affiliation:

1. University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, USA;

2. Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA

Abstract

This commentary addresses salvage therapy of advanced urothelial carcinoma and the importance of prognostic classification. Patients should be referred to one of the important clinical trials of salvage therapy rather than treatment with marginally active chemotherapeutic agents.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2015-0077

Reference20 articles.

1. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract;Bellmunt;J Clin Oncol,2009

2. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group;Roth;J Clin Oncol,1994

3. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium;Sweeney;J Clin Oncol,2006

4. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma;Galsky;Invest New Drugs,2007

5. The safety and efficacy of single-agent pemetrexed in platinum resistant advanced urothelial carcinoma: A large single institution experience;Bambury;The Oncologist,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma;Anticancer Research;2020-03

2. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy;BJU International;2016-10-26

3. Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy;British Journal of Cancer;2016-06

4. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma;European Urology;2016-04